← ANALYST RATINGS · TIPRANKS
Jazz Pharmaceuticals (JAZZ): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy0 Hold0 Sell
Ratings of 14 analysts in the last 3 months · top analysts only12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $302, the highest $337, the lowest $271. The average is +43.4% from the last price of $210.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $242 → $243+0.4% | Buy | +15.6% | Reiterated | 17.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $237 → $238+0.4% | Buy | +13.2% | Reiterated | 17.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $225 → $226+0.4% | Hold | +7.5% | Reiterated | 17.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $242 → $243+0.4% | Buy | +15.6% | Reiterated | 17.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $240 → $241+0.4% | Buy | +14.6% | Reiterated | 17.10.26on TipRanks 03:05 | — | |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $310 | Buy | +47.5% | Reiterated | 16.10.26on TipRanks 07:35 | −0.8% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $236 → $235−0.4% | Buy | +11.8% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $325 | Buy | +54.6% | Reiterated | 15.10.26on TipRanks 07:36 | +2.0%next day −0.8% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $271 | Buy | +28.9% | Reiterated | 13.10.26on TipRanks 04:50 | −2.9%next day +0.7% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $307 → $313+2.0% | Buy | +48.9% | Reiterated | 09.10.26on TipRanks 06:55 | −2.4%next day −0.7% · 5 days −1.8% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $299 → $296−1.0% | Buy | +40.8% | Reiterated | 08.10.26on TipRanks 09:05 | −3.4%next day −2.4% · 5 days −3.3% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $281 → $286+1.8% | Buy | +36.0% | Reiterated | 07.10.26on TipRanks 09:10 | +0.2%next day −3.4% · 5 days −8.3% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $310 | Buy | +47.5% | Reiterated | 28.09.26on TipRanks 07:00 | +0.9%next day −2.3% · 5 days −2.1% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $229 | Hold | +8.9% | Reiterated | 25.09.26on TipRanks Sep 26 10:20 | +0.2%next day +0.9% · 5 days −0.7% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $337 | Buy | +60.3% | Initiated | 24.09.26on TipRanks 04:30 | +0.7%next day +0.2% · 5 days −1.0% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $315 → $337+7.0% | Buy | +60.3% | Assigned | 14.09.26on TipRanks Sep 11 08:09 | +1.4%next day +0.5% · 5 days −2.0% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $300 | Buy | +42.7% | Reiterated | 31.08.26on TipRanks Sep 1 08:35 | +2.8%next day −2.1% · 5 days −4.1% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $300 | Buy | +42.7% | Reiterated | 31.08.26on TipRanks Sep 1 04:35 | +2.8%next day −2.1% · 5 days −4.1% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $283 → $322+13.8% | Buy | +53.2% | Assigned | 26.08.26on TipRanks 08:15 | −4.2%next day +0.1% · 5 days −1.4% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $287 → $300+4.5% | Buy | +42.7% | Reiterated | 26.08.26on TipRanks 04:45 | −4.2%next day +0.1% · 5 days −1.4% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $300 | Buy | +42.7% | Reiterated | 10.08.26on TipRanks Aug 11 05:11 | 0.0%next day −3.0% · 5 days −3.1% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $230 → $275+19.6% | Buy | +30.8% | Reiterated | 04.08.26on TipRanks 07:56 | +2.2%next day +0.2% · 5 days −5.1% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $265 → $276+4.2% | Buy | +31.3% | Assigned | 04.08.26on TipRanks 07:51 | +2.2%next day +0.2% · 5 days −5.1% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $252 → $280+11.1% | Buy | +33.2% | Reiterated | 04.08.26on TipRanks 06:45 | +2.2%next day +0.2% · 5 days −5.1% | ↗ |
| Unknown Analyst | Jefferies | $265 → $282+6.4% | Buy | +34.1% | Reiterated | 13.07.26on TipRanks Jul 14 04:31 | −2.0%next day +0.1% · 5 days +3.7% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $239 | Buy | +13.7% | Reiterated | 06.05.26on TipRanks 09:10 | +6.3%next day −0.4% · 5 days +0.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Jazz Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $298 at a price of $232 (+28.6%); now: $298 at $210 (+41.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 24 | 29 | 31 | 46 | 42 | 40 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $6.28 (from $5.74 to $6.95). Last quarter: $5.71.
Sales
Next quarter’s sales estimate — $1.2B (from $1.2B to $1.2B). Last quarter: $1.2B.
Best top-analyst consensus in the sector · Healthcare
About Jazz Pharmaceuticals
- CEO: Renee D. Gala
- Employees: 2,890
- Waterloo Exchange, Dublin, DU, D04 E5W7, IE
- www.jazzpharma.com
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Data from the stock’s TipRanks forecast page, read 31 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗